Bladder cancer
Drug research and approvals for bladder cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 413 studies of bladder cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 57 drug trials for it since 2013, FDA has 0 approved and 1 open orphan designations naming it, and the EU has 3 authorised medicines for it.
- Recruiting worldwide: 413
- Trials authorized in Canada: 57
- FDA orphan approvals: 0
- EU medicines: 3
- EHR Integrated Remote Patient Monitoring to Reduce Readmission for Patients With Bladder Cancer Undergoing CystectomyNCT07912034 · Not applicable · University of Michigan Rogel Cancer Center · starts Nov 5, 2026
- Risk-Enabled Therapy After Initiating EV/Pembro for Bladder CancerNCT07908979 · Phase 2 · Fox Chase Cancer Center · starts Oct 16, 2026
- 1 Year Recurrence After Modified en Bloc Resection (ERBT) vs Transurethral Resection (TURBT) for Large Bladder TumorsNCT07898033 · Phase 3 · dmitry enikeev · starts Jun 8, 2026
- Urinary Cell-Free DNA Liquid Biopsy for Urothelial Cancer Diagnosis and Origin IdentificationNCT07888374 · Not reported · Ruijin Hospital · starts Apr 5, 2026
- Incidental Gallbladder Carcinoma :Incidence and Clinical Significance in Specimens From Routine Cholecystectomies in…NCT07885800 · Not reported · Sohag University · starts Sep 20, 2026
- Inactivated UPEC-FimON for Non Muscle Invasive Bladder Cancer After BCG or Intravesical Chemotherapy FailureNCT07881666 · Phase 1 · Hopec Pharma · starts Oct 25, 2025
- Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as Perioperative Systemic Therapy for…NCT07870577 · Not reported · Comprehensive Cancer Center Munich (CCCM) · starts Jun 1, 2026
- BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing…NCT07869836 · Phase 3 · SystImmune Inc. · starts Nov 1, 2026
- Feasibility of Automatic, Laser-based Distance Control in Persons With Superficial Bladder TumorsNCT07860398 · Not applicable · Optheras AS · starts Oct 2, 2026
How its trials ended
1,410 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 278 whose ending is known, 26% met their primary endpoint, 8% missed it and 66% stopped early.
- Completed, result not reported46633%
- Ongoing45332%
- Status unknown21315%
- Stopped: other or unclear826%
- Met its primary endpoint735%
- Stopped: enrollment or feasibility604%
- Missed its primary endpoint222%
- Stopped: sponsor or business decision201%
- Stopped: lack of efficacy101%
- Stopped: funding6<1%
- Stopped: safety5<1%
| Oct 30, 2026 | A phase 3 study evaluating sacituzumab tirumotecan plus subcutaneous pembrolizumab and berahyaluronidase alfa (MK-3475A) as induction therapy, followed by…MK-2870 / Keytruda sc (MK-3475A) | Merck & Co. (MSD) | Pending |
| Jul 22, 2026 | Active surveillance versus definitive local therapy for patients showing clinical complete response following neoadjuvant therapy for muscle-invasive bladder…Enfortumab vedotin (PADCEV) / Pembrolizumab (keytruda) / Gemcitabine /… | Dr Marie-Pier St-Laurent | Ongoing |
| Jul 21, 2026 | A phase 3, open-label, randomized study to evaluate enfortumab vedotin in combination with pembrolizumab in adult participants with muscle-invasive bladder…Padcev / Keytruda | Pfizer | Ongoing |
| May 1, 2026 | A phase 3, randomized study to evaluate the efficacy and safety of intravesical TARA-002 compared with investigator’s choice of intravesical chemotherapy in…TARA-002 | Protara Therapeutics, Inc | Pending |
| Nov 24, 2025 | Nrg-GU015: the phase III adaptive radiation and chemotherapy for muscle invasive bladder cancer trial (ARCHER)Mitomycin | Nrg Oncology At The American College of Radiology | Ongoing |
| Nov 20, 2025 | A study of intravesical bacillus calmette-guerin (BCG) in combination with ALT-803 (N-803) in patients with non-muscle invasive bladder cancerN-803 (ALT-803, nai) | ImmunityBio | Pending |
| Nov 10, 2025 | A phase II prospective single-arm study of dutasteride in patients with low-grade non-muscle invasive bladder cancerDutasteride | Chu De Québec-Université Laval | Pending |
| May 2, 2025 | A phase 2, multi-arm, multi-cohort, open-label study to evaluate the safety and efficacy of cretostimogene grenadenorepvec in participants with high-risk…Cretostimogene grenadenorepvec, ddm | CG Oncology | Ongoing |
| Apr 16, 2025 | Randomized phase II trial of pembrolizumab and radiation vs. radiation and concurrent chemotherapy for high-grade T1 bladder cancer (parrc trial)Keytruda (pembrolizumab) | Nrg Oncology | Pending |
| Mar 6, 2025 | A phase 2 open-label randomized study of V940 in combination with bcg versus bcg monotherapy in participants with high-risk non-muscle invasive bladder cancer…V940 (MRNA-4157) / Oncotice (bacillus calmette-guérin (BCG) strain tice) | Merck & Co. (MSD) | Ongoing |
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Jul 31, 2007 | Sodium ascorbate and menadione sodium bisulfiteTreatment of metastatic or locally advanced inoperable transitional cell carcinoma of the urothelium (stage III and IV bladder cancer) | IC-MedTech Corporation | Designated |
| May 28, 2026 | AdstiladrinNadofaragene firadenovec | Ferring Pharmaceuticals A/S | EMA ↗ |
| Feb 16, 2026 | AnktivaNogapendekin alfa inbakicept | Immunitybio Ireland Limited | EMA ↗ |
| Apr 13, 2022 | PadcevEnfortumab vedotin | Astellas Pharma Europe B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA